Hemispherx Biopharma Inc., of Orlando, Fla., said the new Ampligen (rintatolimod) batch manufactured earlier this year is now released for patients' use in the pancreatic cancer early access program (EAP) in the Netherlands pursuant to the terms of the agreement with the company's EAP provider. This is the initial shipment (500 vials) of a previously disclosed 2,100 vial standing stock order, Hemispherx said.